TITLE

Pathology/cytology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS72
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Statistical analysis of pathologic risk factors for intramyometrial lymph/vascular space (LVS) involvement in myoinvasive endometrial carcinoma,' by D. Wenzel et al.
ACCESSION #
9708236887

 

Related Articles

  • Estradiol/estradiol congeners.  // Reactions Weekly;8/18/2012, Issue 1415, p21 

    The article describes the case of 78-year-old woman who developed endometrioid adenocarcinoma after receiving oestrogen hormone replacement therapy (HRT) with estradiol implants and subsequently estradiol congener patches for endometriosis.

  • Coffee Drinking Linked with Lower Risk of Endometrial Cancer. Dye, D. // Life Extension;Mar2012, Vol. 18 Issue 3, p1 

    The article discusses research which was conducted by a team of researchers at Harvard University led by Youjin Je, was reported in the journal "Cancer Epidemiology, Biomarkers & Prevention" and found that there was an association between coffee consumption and a reduced risk of endometrial cancer.

  • Active women are less likely to develop endometrial cancer.  // Nursing Standard;7/14/2010, Vol. 24 Issue 45, p17 

    An abstract of the article “Lifetime physical activity and risk of endometrial cancer,” by E. J. John and others, published in a 2010 issue of "Cancer Epidemiology, Biomarkers and Prevention," is presented.

  • Use of Oral Contraceptives and Endometrial Cancer Risk.  // American Family Physician;5/1/1994, Vol. 49 Issue 6, p1495 

    Presents a study by Jick and colleagues on the relationship between past history of oral contraceptive use and development of endometrial cancer. Inclusion of American women aged 50 to 64 years old; Analysis of data using the logistic regression models. `Obstetrics and Gynecology,' December...

  • Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins. Weiderpass, Elisabete; Hans-Olov; Adami; Baron, John A.; Magnusson, Cecilia; Bergstrom, Reinhold; Lindgren, Anders; Correia, Nestor; Persson, Ingemar // JNCI: Journal of the National Cancer Institute;07/07/99, Vol. 91 Issue 13, p1131 

    Deals with the study which assessed the impact of different hormone replacement regimens on endometrial cancer risk where estrogens with progestins have been widely used in Sweden. Characteristics of the study participants; Intake of estrogens with and without progestins; Association of hormone...

  • CPS-II: Adult weight gain associated with increased risk for endometrial cancer. Stevens, Victoria L. // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p35 

    The article presents a study that deals with the increased risk for endometrial cancer to women who gained substantial amounts of weight.

  • Unopposed low-dose estrogen does increase the risk of endometrial cancer.  // Modern Medicine;Apr98, Vol. 66 Issue 4, p47 

    Presents an abstract of the article `Risk of Endometrial Cancer in Relation to Use of Low-Dose, Unopposed Estrogens,' by K.L. Cushing, N.S. Weiss, et al from `Obstetric Gynecology' dated January 1998.

  • Study clarifies tamoxifen's role in endometrial cancer risk. Lucas, Beverly D. // Patient Care;12/15/1999, Vol. 33 Issue 20, p15 

    Presents the findings of a study on the role of tamoxifen in determining endometrial cancer risks. High incidences of cancer risk for women administered with tamoxifen; Positive association of tamoxifen therapy with endometrial cancer; Correlation of body mass index with endometrial cancer.

  • The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. S. Duffy; T.L. Jackson; M. Lansdown; K. Philips; M. Wells; S. Pollard; G. Clack; M. Coibion; A.R. Bianco // Human Reproduction;Feb2006, Vol. 21 Issue 2, p545 

    BACKGROUND: Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1–2 years of treatment and a quadrupling after 5 years. Anastrozole, a third-generation aromatase inhibitor, with superior efficacy to tamoxifen, may also offer tolerability benefits in terms of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics